EA202092574A1 - Композиции и способы обнаружения и лечения рака яичников - Google Patents

Композиции и способы обнаружения и лечения рака яичников

Info

Publication number
EA202092574A1
EA202092574A1 EA202092574A EA202092574A EA202092574A1 EA 202092574 A1 EA202092574 A1 EA 202092574A1 EA 202092574 A EA202092574 A EA 202092574A EA 202092574 A EA202092574 A EA 202092574A EA 202092574 A1 EA202092574 A1 EA 202092574A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
ovarian cancer
compositions
detecting
treating ovarian
Prior art date
Application number
EA202092574A
Other languages
English (en)
Inventor
Александр Приёр
Original Assignee
Прогастрин Э Кансер С.А Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прогастрин Э Кансер С.А Р.Л. filed Critical Прогастрин Э Кансер С.А Р.Л.
Publication of EA202092574A1 publication Critical patent/EA202092574A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к способам in vitro диагностики рака яичников, а также к композиции и способам профилактики или лечения рака яичников, где указанные композиции содержат антитело, связывающееся с прогастрином, а указанные способы включают применение антитела, связывающегося с прогастрином.
EA202092574A 2016-02-05 2017-01-02 Композиции и способы обнаружения и лечения рака яичников EA202092574A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305138 2016-02-05

Publications (1)

Publication Number Publication Date
EA202092574A1 true EA202092574A1 (ru) 2021-05-31

Family

ID=55310772

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092574A EA202092574A1 (ru) 2016-02-05 2017-01-02 Композиции и способы обнаружения и лечения рака яичников

Country Status (1)

Country Link
EA (1) EA202092574A1 (ru)

Similar Documents

Publication Publication Date Title
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
EA202091540A1 (ru) Антитела к lilrb2
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201891983A8 (ru) Комбинированная терапия антителами к cd73
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA202092435A3 (ru) Моноклональные антитела против bcma
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201790413A1 (ru) Антитела против tigit
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
CO2017005941A2 (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
EA201691541A1 (ru) Новые анти-baff антитела
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201592203A1 (ru) Способы лечения таупатии
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
EA201892716A1 (ru) Антитела к фактору свертывания xi